Antiviral Treatment of Chronic Lymphocytic Leukemia

Phase 4

Completed

• Conditions: Chronic Lymphocytic Leukemia
• Interventions: Drug: Valganciclovir

• Registration Number: NCT01255644
• Lead Sponsor: Medical University of Vienna

Brief Summary

Chronic lymphocytic leukemia (CLL) is increasingly believed to be closely related to chronic stimulation of healthy B-cells. Identification of antigen(s) are relevant for the stimulation of CLL precursor cells is therefore of high interest. The investigators found recently evidence that a herpes virus is involved in this process of stimulation. Consequently, elimination of the antigenic stimulation of leukemic cells by this herpes virus may be expected to reduce or even inhibit propagation of leukemic cells. The investigators hypothesize that inhibition of CMV replication by a short course of antiviral treatment may reduce significantly proliferation rates of leukemic cells. To test this hypothesis, the investigators will treat 20 CLL patients with an antiviral drug for 3 months in a proof-of-concept clinical trial and leukemic cell counts measured before and after antiviral treatment. Antiviral treatment has the potential to treat the disease at its origin and therefore more efficiently than conventional chemotherapeutic regimens.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-12
• Study First Submitted: 2010-12-06
• Study First Submitted QC: 2010-12-06
• Study First Posted: 2010-12-07
• Status Verified: 2015-07
• Primary Completion: 2015-07
• Study Completion: 2015-07
• Last Update Submitted: 2015-07-20
• Last Update Posted: 2015-07-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• CLL confirmed by immunophenotyping and a relative preponderance of leukemic cells of >70%
• ANC >1.500 /µl, Thrombocyte count >100.000 /µl und hemoglobin value >11 g/dl
• CLL patients with expression of immunoglobulin heavy chains (IGHV) 1-69 or 3-21
• Seropositive for CMV-specific IgG-antibodies
• Older than 18 years of age
• Written informed consent
• Able to comply with the protocol
• If female, should not be pregnant or be breast-feeding. Women of child-bearing age must have a negative serum pregnancy test within 28days prior to enrollment into the study, if a serum pregnancy test is not performed within 7 days prior first IMP administration; a confirmatory urine test is required.

Exclusion Criteria

• Indications for treatment of CLL (advanced stages of the disease)
• Having receiving chemotherapy for CLL within 3 months prior to enrollment
• Having received antiviral drugs or i.v. immunoglobulins within 3 months prior to enrollment
• Significant thrombocytopenia (<100.000/µl) or anemia (Hb < 11 g/dl)
• Women of child bearing age not using effective contraception
• Pregnant of lactating female (as determined by a positive pregnancy test at screening or within 7 days prior to first IMP administration)
• Known hypersensitivity to drug or its excipients

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Antiviral drug	Valganciclovir	-

Primary Outcome Measures

Name	Time	Method
Leukocyte count	Month 12

Trial Locations

Locations (1)

Medical University of Vienna; 🇦🇹 Vienna, Austria